Search Within

David J Straus

Formats
  1. Meeting Abstract (166)
  2. Journal Article (165)
  3. Book Section (15)
  4. Conference Paper (5)
  5. Research Letter (3)
  6. Editorial (2)
  7. Correspondence (1)
  8. Review (1)
Groups
  1. Center for Hematologic Malignancies (358)
  2. Department of Medicine (358)
  3. Hematologic Malignancies, Division of (358)
  4. Lymphoma (358)
  5. Survivorship Research (160)
  6. Population Sciences Research Program (127)

More Groups

People
  1. Andrew Zelenetz (161)
  2. Ariela Noy (137)
  3. Paul Hamlin (120)
  4. Steven Horwitz (120)
  5. Craig Moskowitz (117)
  6. Matthew Matasar (103)

More People

Years
  1. 2024 (7)
  2. 2023 (9)
  3. 2022 (13)
  4. 2021 (27)
  5. 2020 (25)
  6. 2019 (21)

More Years

Publications
  1. Blood (115)
  2. Journal of Clinical Oncology (44)
  3. Hematological Oncology (19)
  4. Cancer (14)
  5. Leukemia and Lymphoma (13)
  6. British Journal of Haematology (11)

More Publications

Publishers
  1. American Society of Hematology (122)
  2. American Society of Clinical Oncology (46)
  3. Wiley Blackwell (36)
  4. Elsevier Inc. (22)
  5. Taylor & Francis Group (14)
  6. John Wiley & Sons (12)

More Publishers

Results (358)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Devimistat results in a low complete remission rate in heavily pre-treated Burkitt lymphoma
    Meeting Abstract

    Steiner, R.; Nikolaenko, L.; Kambhampati, S.; Khan, N.; Nair, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez Rivera, I. I.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Seven-year overall survival analysis from ECHELON-1 study of A+ AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma
    Meeting Abstract

    Ansell, S. M.; Straus, D. J.; Connors, J. M.; Jurczak, W.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R. H.; Hutchings, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
    Journal Article

    Bantilan, K. S.; Smith, A. N.; Maurer, M. J.; Teruya-Feldstein, J.; Matasar, M. J.; Moskowitz, A. J.; Straus, D. J.; Noy, A.; Palomba, M. L.; Horwitz, S. M.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
    Research Letter

    Crosswell, H. E.; LaCasce, A. S.; Bartlett, N. L.; Straus, D. J.; Savage, K. J.; Zinzani, P. L.; Collins, G. P.; Fanale, M.; Fenton, K.; Dong, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C)
    Meeting Abstract

    Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Improved overall survival in stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
    Meeting Abstract

    Collins, G. P.; Ansell, S. M.; Straus, D. J.; Connors, J. M.; Dlugosz-Danecka, M.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save